experts urge caution.
While early research has shown promise, larger studies remain necessary to better understand long-term safety, effectiveness, appropriate patient selection, and possible risks. Regulators must ensure that accelerated review does not compromise the rigorous scientific standards designed to protect patients.
Critics of the executive continue reading …
